RNAi Outsider Senetek Looking for Pharma Partner to Develop, Sell Its Brain Cancer Rx

Armed with an in-licensed RNAi-based brain cancer drug, Senetek concedes it has “no capabilities” to develop it but hopes to find a partner from among its “significant relationships with pharmaceutical companies” that can develop and commercialize the product.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.